Tyra Biosciences, Inc. (NASDAQ:TYRA) CEO Sells $397,934.90 in Stock

by · The Markets Daily

Tyra Biosciences, Inc. (NASDAQ:TYRA – Get Free Report) CEO Todd Harris sold 15,394 shares of Tyra Biosciences stock in a transaction that occurred on Thursday, October 17th. The stock was sold at an average price of $25.85, for a total value of $397,934.90. Following the completion of the transaction, the chief executive officer now directly owns 1,418,647 shares in the company, valued at approximately $36,672,024.95. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Todd Harris also recently made the following trade(s):

  • On Tuesday, October 15th, Todd Harris sold 10,035 shares of Tyra Biosciences stock. The stock was sold at an average price of $24.31, for a total transaction of $243,950.85.
  • On Monday, September 30th, Todd Harris sold 500 shares of Tyra Biosciences stock. The stock was sold at an average price of $24.00, for a total transaction of $12,000.00.
  • On Wednesday, September 25th, Todd Harris sold 600 shares of Tyra Biosciences stock. The shares were sold at an average price of $24.01, for a total transaction of $14,406.00.
  • On Monday, September 23rd, Todd Harris sold 10,092 shares of Tyra Biosciences stock. The stock was sold at an average price of $24.13, for a total value of $243,519.96.
  • On Thursday, September 19th, Todd Harris sold 5,698 shares of Tyra Biosciences stock. The shares were sold at an average price of $24.31, for a total value of $138,518.38.

Tyra Biosciences Stock Performance

Shares of NASDAQ TYRA traded up $0.08 during midday trading on Thursday, hitting $25.98. 176,569 shares of the stock traded hands, compared to its average volume of 150,106. Tyra Biosciences, Inc. has a one year low of $10.38 and a one year high of $27.17. The business has a 50 day moving average price of $22.06 and a two-hundred day moving average price of $19.37. The company has a market cap of $1.37 billion, a PE ratio of -15.37 and a beta of 1.01.

Tyra Biosciences (NASDAQ:TYRA – Get Free Report) last announced its quarterly earnings results on Wednesday, August 7th. The company reported ($0.32) EPS for the quarter, beating analysts’ consensus estimates of ($0.41) by $0.09. As a group, equities research analysts forecast that Tyra Biosciences, Inc. will post -1.53 EPS for the current fiscal year.

Analyst Ratings Changes

TYRA has been the subject of a number of research analyst reports. HC Wainwright lifted their target price on Tyra Biosciences from $25.00 to $30.00 and gave the stock a “buy” rating in a report on Monday, October 7th. Oppenheimer lifted their price objective on shares of Tyra Biosciences from $25.00 to $33.00 and gave the company an “outperform” rating in a research note on Thursday, September 19th. Piper Sandler began coverage on shares of Tyra Biosciences in a research note on Thursday, August 15th. They set an “overweight” rating and a $33.00 target price on the stock. Finally, Wedbush reaffirmed an “outperform” rating and issued a $28.00 price target on shares of Tyra Biosciences in a research note on Thursday, August 8th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $27.80.

View Our Latest Research Report on TYRA

Institutional Investors Weigh In On Tyra Biosciences

Several hedge funds and other institutional investors have recently made changes to their positions in TYRA. HighVista Strategies LLC bought a new position in Tyra Biosciences in the 2nd quarter valued at about $257,000. SG Americas Securities LLC purchased a new stake in shares of Tyra Biosciences in the third quarter worth approximately $311,000. Rhumbline Advisers lifted its stake in Tyra Biosciences by 12.3% during the 2nd quarter. Rhumbline Advisers now owns 23,572 shares of the company’s stock valued at $377,000 after acquiring an additional 2,574 shares in the last quarter. Bank of New York Mellon Corp lifted its position in shares of Tyra Biosciences by 32.8% during the second quarter. Bank of New York Mellon Corp now owns 58,087 shares of the company’s stock valued at $929,000 after purchasing an additional 14,352 shares in the last quarter. Finally, Oppenheimer & Co. Inc. purchased a new position in shares of Tyra Biosciences in the 1st quarter worth approximately $977,000. 84.14% of the stock is owned by institutional investors.

About Tyra Biosciences

(Get Free Report)

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.

Further Reading